furofuran - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	furofuran	go back to main search page
Accession:	CHEBI:47790	browse the term
Definition:	Organic heterobicyclic compounds containing a two furan rings ortho-fused to each other.
Synonyms:	related_synonym:	furofurans

show annotations for term's descendants Sort by:
Rat (67 ) Mouse (67 ) Human (67 ) Chinchilla (0 ) Bonobo (0 ) Dog (0 ) Squirrel (0 ) Pig (0 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (67)

(+)-pinoresinol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

multiple interactions
decreases expression

ISO

[loliolide co-treated with pinoresinol] results in decreased expression of ACACA protein
pinoresinol results in decreased expression of ACACA protein

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

fatty acid synthase

multiple interactions
decreases expression

ISO

[loliolide co-treated with pinoresinol] results in decreased expression of FASN protein
pinoresinol results in decreased expression of FASN protein

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

nuclear receptor subfamily 1, group H, member 2

multiple interactions

ISO

pinoresinol results in increased ubiquitination of and results in increased degradation of and results in decreased expression of NR1H2 protein

NCBI chr 1:104,178,483...104,183,863
Ensembl chr 1:104,178,234...104,183,863

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

ISO

pinoresinol results in increased ubiquitination of and results in increased degradation of and results in decreased expression of NR1H3 protein

NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

pinoresinol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

sterol regulatory element binding transcription factor 1

decreases expression
multiple interactions

ISO

pinoresinol results in decreased expression of SREBF1 protein
[loliolide co-treated with pinoresinol] results in decreased expression of SREBF1 protein

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

tumor necrosis factor

decreases secretion

ISO

pinoresinol results in decreased secretion of TNF protein

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

ISO

[sesamin affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions

EXP

sesamin affects the reaction [Glucose affects the localization of AIFM1 protein]

NCBI chr X:132,528,107...132,567,237
Ensembl chr X:132,528,107...132,567,237

G

BCL2 associated X, apoptosis regulator

multiple interactions

ISO
EXP

sesamin inhibits the reaction [nickel sulfate results in increased expression of BAX protein]
sesamin affects the reaction [Glucose affects the expression of BAX protein]

PMID:22524206 PMID:23317420

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

ISO
EXP

sesamin inhibits the reaction [nickel sulfate results in decreased expression of BCL2 protein]
sesamin affects the reaction [Glucose affects the expression of BCL2 protein]

PMID:22524206 PMID:23317420

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

caspase 3

multiple interactions

ISO
EXP

sesamin inhibits the reaction [nickel sulfate results in increased cleavage of CASP3 protein]
sesamin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]

PMID:22524206 PMID:23317420

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

catalase

decreases activity
multiple interactions

EXP
ISO

sesamin results in decreased activity of CAT protein
sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CAT protein]; sesamin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]
sesamin inhibits the reaction [nickel sulfate results in decreased activity of CAT protein]

PMID:19794909 PMID:23317420 PMID:26825964

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

cadherin 1

increases expression

ISO

sesamin results in increased expression of CDH1 mRNA; sesamin results in increased expression of CDH1 protein

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

catenin beta 1

increases expression

ISO

sesamin results in increased expression of CTNNB1 mRNA; sesamin results in increased expression of CTNNB1 protein

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

fatty acid desaturase 1

decreases activity

EXP

sesamin results in decreased activity of FADS1 protein

NCBI chr 1:216,252,605...216,267,618
Ensembl chr 1:216,252,602...216,267,615

G

glutathione-disulfide reductase

increases activity

EXP

sesamin results in increased activity of GSR protein

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

interleukin 1 beta

multiple interactions

ISO

sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B mRNA]; sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B protein]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions

ISO
EXP

sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 mRNA]; sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]

PMID:19794909 PMID:22919443

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

nitric oxide synthase 2

decreases expression
multiple interactions

EXP

sesamin results in decreased expression of NOS2 protein
sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOS2 protein]

PMID:19794909 PMID:22919443

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

poly (ADP-ribose) polymerase 1

multiple interactions

EXP

sesamin inhibits the reaction [Glucose results in increased cleavage of PARP1 protein]

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

superoxide dismutase 2

multiple interactions

EXP

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [sesamin inhibits the reaction [Doxorubicin results in decreased expression of and results in decreased activity of SOD2 protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [sesamin results in increased expression of and results in increased activity of SOD2 protein]; sesamin inhibits the reaction [Doxorubicin results in decreased expression of and results in decreased activity of SOD2 protein]; sesamin results in increased expression of and results in increased activity of SOD2 protein

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

tyrosine hydroxylase

multiple interactions

EXP

sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TH protein]

NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227

G

tumor necrosis factor

multiple interactions

ISO

sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF mRNA]; sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

(+)-syringaresinol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

syringaresinol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiopoietin 2

decreases expression

ISO

norcantharidin results in decreased expression of ANGPT2 mRNA; norcantharidin results in decreased expression of ANGPT2 protein

NCBI chr16:77,790,760...77,841,241
Ensembl chr16:77,790,563...77,841,239

G

activating transcription factor 4

multiple interactions
increases expression

ISO

[norcantharidin co-treated with Paclitaxel] results in increased expression of ATF4 protein; Paclitaxel promotes the reaction [norcantharidin results in increased expression of ATF4 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased expression of ATF4 protein]

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

aurora kinase A

multiple interactions

ISO

[Paclitaxel results in decreased susceptibility to norcantharidin] which results in increased expression of AURKA protein

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771

G

BCL2-associated agonist of cell death

increases expression

ISO

norcantharidin results in increased expression of BAD protein

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

BCL2-antagonist/killer 1

increases expression

ISO

norcantharidin results in increased expression of BAK1 protein alternative form

NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974

G

BCL2 associated X, apoptosis regulator

increases expression

ISO

norcantharidin results in increased expression of BAX protein

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

increases phosphorylation
decreases expression

ISO

norcantharidin results in increased phosphorylation of BCL2 protein
norcantharidin results in decreased expression of BCL2 protein

PMID:21266192 PMID:29193574

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

decreases expression

ISO

norcantharidin results in decreased expression of BCL2L1 protein

PMID:21266192 PMID:29193574

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

Bcl2-like 11

increases expression

ISO

norcantharidin results in increased expression of BCL2L11 protein alternative form

NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695

G

BH3 interacting domain death agonist

increases expression

ISO

norcantharidin results in increased expression of BID protein modified form

NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275

G

caspase 3

increases activity
multiple interactions
increases expression

ISO

norcantharidin results in increased activity of CASP3 protein
Paclitaxel promotes the reaction [norcantharidin results in increased expression of CASP3 protein modified form]; U 0126 inhibits the reaction [norcantharidin results in increased expression of CASP3 protein modified form]

PMID:20040369 PMID:21266192 PMID:29193574 PMID:34272796

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

increases expression
increases activity
multiple interactions

ISO

norcantharidin results in increased expression of CASP8 protein modified form
norcantharidin results in increased activity of CASP8 protein
Paclitaxel promotes the reaction [norcantharidin results in increased expression of CASP8 protein modified form]; U 0126 inhibits the reaction [norcantharidin results in increased expression of CASP8 protein modified form]

PMID:20040369 PMID:21266192 PMID:29193574 PMID:34272796

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

multiple interactions
increases activity
increases expression

ISO

Paclitaxel promotes the reaction [norcantharidin results in increased expression of CASP9 protein modified form]
norcantharidin results in increased activity of CASP9 protein

PMID:20040369 PMID:21266192 PMID:29193574 PMID:34272796

Ensembl chr 5:159,391,188...159,409,648

G

cellular communication network factor 2

decreases expression

EXP

norcantharidin results in decreased expression of CCN2 mRNA; norcantharidin results in decreased expression of CCN2 protein

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

cyclin B1

decreases expression
multiple interactions

ISO

norcantharidin results in decreased expression of CCNB1 protein
Paclitaxel promotes the reaction [norcantharidin results in decreased expression of CCNB1 protein]

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cell division cycle 25C

multiple interactions
decreases expression

ISO

Paclitaxel promotes the reaction [norcantharidin results in decreased expression of CDC25C protein]

PMID:21266192 PMID:34272796

NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,609,959...26,630,292

G

cadherin 2

decreases expression

ISO

norcantharidin results in decreased expression of CDH2 protein

NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288

G

cyclin-dependent kinase inhibitor 1A

increases phosphorylation

ISO

norcantharidin results in increased phosphorylation of CDKN1A protein

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

checkpoint kinase 1

increases phosphorylation

ISO

norcantharidin results in increased phosphorylation of CHEK1 protein

NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359

G

checkpoint kinase 2

increases phosphorylation

ISO

norcantharidin results in increased phosphorylation of CHEK2 protein

NCBI chr12:51,448,838...51,481,159
Ensembl chr12:51,449,140...51,480,667

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

ISO

norcantharidin results in increased expression of DDIT3 protein
[norcantharidin co-treated with Paclitaxel] results in increased expression of DDIT3 protein; Paclitaxel promotes the reaction [norcantharidin results in increased expression of DDIT3 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased expression of DDIT3 protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

desmoglein 1

decreases expression

ISO

norcantharidin results in decreased expression of DSG1 protein

NCBI chr18:11,948,098...11,980,455
Ensembl chr18:11,949,488...11,980,451

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation
multiple interactions

ISO

norcantharidin results in increased phosphorylation of EIF2S1 protein
[norcantharidin co-treated with Paclitaxel] results in increased phosphorylation of EIF2S1 protein; Paclitaxel promotes the reaction [norcantharidin results in increased phosphorylation of EIF2S1 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions
increases expression

ISO

Paclitaxel promotes the reaction [norcantharidin results in increased expression of ERN1 protein]

NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791

G

Fas cell surface death receptor

increases expression

ISO

norcantharidin results in increased expression of FAS protein

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

H2A.X variant histone

increases expression
multiple interactions

ISO

norcantharidin results in increased expression of H2AX protein modified form
Paclitaxel promotes the reaction [norcantharidin results in increased expression of H2AX protein modified form]

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

interleukin 2

multiple interactions

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]]; norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; SB 203580 inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]]

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

mitogen activated protein kinase 1

increases phosphorylation

ISO

norcantharidin results in increased phosphorylation of MAPK1 protein

PMID:21075198 PMID:21266192

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

increases phosphorylation

ISO

norcantharidin results in increased phosphorylation of MAPK3 protein

PMID:21075198 PMID:21266192

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 8

increases phosphorylation

ISO

norcantharidin results in increased phosphorylation of MAPK8 protein

PMID:21266192 PMID:29193574

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

mitogen-activated protein kinase 9

increases phosphorylation

ISO

norcantharidin results in increased phosphorylation of MAPK9 protein

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression

ISO

norcantharidin results in decreased expression of MCL1 protein

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

matrix metallopeptidase 2

decreases activity

ISO

norcantharidin results in decreased activity of MMP2 protein

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

multiple interactions
decreases activity
decreases expression

ISO

norcantharidin results in decreased expression of and results in decreased activity of MMP9 protein; SP1 protein affects the reaction [norcantharidin results in decreased expression of MMP9 mRNA]
norcantharidin results in decreased activity of MMP9 protein

PMID:15711181 PMID:19616522

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

poly (ADP-ribose) polymerase 1

increases expression
multiple interactions

ISO

norcantharidin results in increased expression of PARP1 protein modified form
[norcantharidin co-treated with Paclitaxel] results in increased cleavage of PARP1 protein; Paclitaxel promotes the reaction [norcantharidin results in increased expression of PARP1 protein modified form]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased cleavage of PARP1 protein]

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

proliferating cell nuclear antigen

decreases expression

ISO

norcantharidin results in decreased expression of PCNA protein

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

RELA proto-oncogene, NF-kB subunit

decreases expression

EXP

norcantharidin results in decreased expression of RELA mRNA; norcantharidin results in decreased expression of RELA protein

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

sirtuin 2

decreases expression

ISO

norcantharidin results in decreased expression of SIRT2 mRNA

NCBI chr 1:93,181,472...93,204,499
Ensembl chr 1:93,181,224...93,204,499

G

sirtuin 6

decreases expression

ISO

norcantharidin results in decreased expression of SIRT6 mRNA

NCBI chr 7:8,733,056...8,738,543
Ensembl chr 7:8,732,974...8,738,542

G

sirtuin 7

multiple interactions
decreases expression

ISO

[norcantharidin co-treated with Paclitaxel] results in decreased expression of and affects the localization of SIRT7 protein; [norcantharidin co-treated with Paclitaxel] results in decreased expression of SIRT7 mRNA; Paclitaxel promotes the reaction [norcantharidin results in decreased expression of SIRT7 mRNA]; Paclitaxel promotes the reaction [norcantharidin results in decreased expression of SIRT7 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased cleavage of PARP1 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased expression of ATF4 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased expression of DDIT3 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased phosphorylation of EIF2S1 protein]
norcantharidin results in decreased expression of SIRT7 mRNA; norcantharidin results in decreased expression of SIRT7 protein

NCBI chr10:106,394,802...106,401,627
Ensembl chr10:106,394,802...106,401,498

G

Sp1 transcription factor

multiple interactions
decreases activity

ISO

SP1 protein affects the reaction [norcantharidin results in decreased expression of MMP9 mRNA]
norcantharidin results in decreased activity of SP1 protein

NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:135,420,050...135,450,513

G

signal transducer and activator of transcription 1

increases expression

ISO

norcantharidin results in increased expression of STAT1 protein

NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346

G

signal transducer and activator of transcription 3

decreases phosphorylation

ISO

norcantharidin results in decreased phosphorylation of STAT3 protein

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

signal transducer and activator of transcription 5A

decreases phosphorylation

ISO

norcantharidin results in decreased phosphorylation of STAT5A protein

NCBI chr10:86,285,859...86,310,187
Ensembl chr10:86,285,547...86,310,184

G

signal transducer and activator of transcription 5B

decreases phosphorylation

ISO

norcantharidin results in decreased phosphorylation of STAT5B protein

NCBI chr10:86,205,148...86,276,178
Ensembl chr10:86,207,293...86,275,990

G

thrombospondin 1

increases expression

ISO

norcantharidin results in increased expression of THBS1 protein

NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402

G

TIMP metallopeptidase inhibitor 2

increases expression

ISO

norcantharidin results in increased expression of TIMP2 mRNA; norcantharidin results in increased expression of TIMP2 protein

NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214

G

vascular endothelial growth factor A

decreases expression

ISO

norcantharidin results in decreased expression of VEGFA mRNA; norcantharidin results in decreased expression of VEGFA protein

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	20874
chemical entity	20872
atom	20872
nonmetal atom	20781
oxygen atom	20437
oxygen molecular entity	20437
organooxygen compound	19713
oxacycle	18273
furofuran	67
(+)-(7R,7'R,7''R,7'''R,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9':7',9-diepoxy-4,8'':4',8'''-bisoxy-8,8'-dineolignan-7'',7''',9'',9'''-tetraol	0
(+)-(7R,7'R,7''R,7'''S,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9':7',9-diepoxy-4,8'':4',8'''-bisoxy-8,8'-dineolignan-7'',7''',9'',9'''-tetraol	0
(+)-(7R,7'R,7''S,7'''S,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9':7',9-diepoxy-4,8'':4',8'''-bisoxy-8,8'-dineolignan-7'',7''',9'',9'''-tetraol	0
(+)-sesamin	17
(+)-sesamin dicatechol	0
(+)-sesamin monocatechol	0
(-)-(7R,7'R,7''R,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5',5''-hexamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol	0
(-)-(7R,7'R,7''R,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5'-pentamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol	0
(-)-(7R,7'R,7''R,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5-tetramethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol	0
(-)-(7R,7'R,7''S,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5',5''-hexamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol	0
(-)-(7R,7'R,7''S,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5'-pentamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol	0
(-)-(7R,7'R,7''S,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5-tetramethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol	0
(-)-(7R,7'R,8S,8'S)-4'-hydroxy-3,3',4,5,5'-pentamethoxy-7,9':7',9-diepoxylignane	0
(-)-demethoxylpinoresinol	0
(-)-medioresinol	0
(1S,3R,7Z,9R,12S,13R,15R)-13-Hydroxy-3,7,12-trimethyl-13-prop-1-en-2-yl-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-diene-4,11-dione	0
(1S,7Z,9R,12S,13R,15R)-13-Hydroxy-3,7,12-trimethyl-13-propan-2-yl-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-diene-4,11-dione	0
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-\{4-[(2-methyl-1,3-thiazol-4-yl)methoxy]benzyl\}propyl]carbamate	0
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl glycolate	0
11,12-epoxy-5,6-seco-1,6(13)-tremuladien-5,12-olide	0
13-Hydroxymarasmene	0
14,15-dihydroajugapitin	0
14,15-dihydroclerodin	0
14-hydro-15-hydroxyajugachin A	0
14-hydro-15-hydroxyajugapitin	0
15-Hydroxymarasmen-3-one	0
15-epi-lupulin B	0
15-hydroxyajubractin C	0
1alpha,15-Dihydroxymarasmene	0
22-epi-methylatranone B	0
3-epi-14,15-dihydrocaryoptin	0
3-epi-caryoptin	0
3alpha,15-Dihydroxymarasmene	0
3beta-Dihydroxymarasmene	0
4-[(1S,3aR,4S,6aR)-4-(1,3-benzodioxol-5-yl)tetrahydrofuro[3,4-c]furan-1-yl]-2-methoxyphenol	0
4-epi-Ethiosolide	0
4alpha-hydroxypinoresinol	0
4beta-[(beta-D-glucopyranosyl)hydroxy]-pinoresinol	0
6-(7-methyloctyl)-1H,3H,4H,6H-furo[3,4-c]furan-1-one	0
6-hexyl-3-methyl-(3S,3aS,6R,6aR)-perhydrofuro[3,4-b]furan-2,4-dione	0
Agrocybolactone	0
Anhydromarasmone	0
Ascospiroketal A	0
Ascospiroketal B	0
Asperochrin E	0
Aspersclerotiorone C	0
Asteltoxin	0
Asteltoxin B	0
Asteltoxin C	0
Asteltoxin D	0
Asteltoxin E	0
Asteltoxin F	0
Atranone A	0
Atranone B	0
Atranone C	0
Atranone H	0
Atranone I	0
Atranone T	0
Atranone U	0
Avenaciolid 1	0
Avenaciolid 4	0
Avertoxin A	0
Avertoxin B	0
Avertoxin C	0
Avertoxin D	0
Cephalosporolide E	0
Cephalosporolide F	0
Cephalosporolide H	0
Cephalosporolide I	0
Clerodendrin A	0
Communiol D	0
Conosilane A	0
Dermatolactone	0
Diasteltoxin A	0
Diasteltoxin B	0
Diasteltoxin C	0
Dibetaeminin A	0
Dihydromarasmone	0
Discosiolide	0
Eremantholide A	0
Erythroskyrin	0
GS-8373	0
Gilluone A	0
Gymnodrimane D	0
Isoasteltoxin	0
Isomarasmone	0
Jodrellin A	0
LSM-4433	0
Mabetaarilactone A	0
Mabetaarilactone F	0
Mabetaarilactone acetonide	0
Manginoid E	0
Manginoid F	0
Marasmene	0
Marasmene B	0
Marasmone	0
NORCANTHARIDIN	48
Neglectine A	0
Nesteretal A	0
No. 2106 A	0
Penisporolide B	0
Protulactone A	0
Pseudonocardide D	0
Purpurogenolide A	0
Pyrenolide D	0
Rubetaulanorol-beta	0
Sculponeatin C	0
Spiroleptosphol T1	0
Spiroleptosphol T2	0
Spiroleptosphol W	0
Spiromabetaaritone	0
Syringolide 1	0
Syringolide 2	0
Taichunin A	0
Trichodermaketone A	0
Trichodermaketone B	0
Trichodermaketone E	0
V214w	0
Varioxiranol L	0
Velleratretraol	0
Virgineol	0
Xylobovide	0
[(1S,3R,7Z,9R,12S,13R,15R)-13-Butan-2-yl-13-hydroxy-3,12-dimethyl-4,11-dioxo-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-dien-7-yl]methyl acetate	0
ajubractin A	0
ajubractin B	0
ajubractin C	0
ajubractin D	0
ajubractin E	0
ajugapitin	0
alpha-mannofuranuronic acid gamma-lactone	0
aplysiallene	0
areptin A	0
areptin B	0
buddlenol C	0
caryoptin	0
clerodin	0
darunavir +	0
demethoxyaschantin	0
dihydrocanadensolide	0
ficusequilignan A	0
ivain II	0
lupulin A	0
pinoresinol +	7
salicifoliol	0
sesaminol	0
sesaminol 2-O-beta-D-gentiobioside	0
sesaminol 2-O-beta-D-glucoside	0
sporothriolide	0
stemocurtisine	0
stemocurtisine N-oxide	0
syringaresinol +	1
Path 2
Term	Annotations
CHEBI ontology	20874
subatomic particle	20883
composite particle	20883
hadron	20872
baryon	20883
nucleon	20872
atomic nucleus	20883
atom	20872
main group element atom	20796
p-block element atom	20796
carbon group element atom	20712
carbon atom	20706
organic molecular entity	20706
organic molecule	20499
organic cyclic compound	20390
organic heterocyclic compound	19381
organic heteropolycyclic compound	18616
organic heterobicyclic compound	17442
furofuran	67
(+)-(7R,7'R,7''R,7'''R,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9':7',9-diepoxy-4,8'':4',8'''-bisoxy-8,8'-dineolignan-7'',7''',9'',9'''-tetraol	0
(+)-(7R,7'R,7''R,7'''S,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9':7',9-diepoxy-4,8'':4',8'''-bisoxy-8,8'-dineolignan-7'',7''',9'',9'''-tetraol	0
(+)-(7R,7'R,7''S,7'''S,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9':7',9-diepoxy-4,8'':4',8'''-bisoxy-8,8'-dineolignan-7'',7''',9'',9'''-tetraol	0
(+)-sesamin	17
(+)-sesamin dicatechol	0
(+)-sesamin monocatechol	0
(-)-(7R,7'R,7''R,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5',5''-hexamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol	0
(-)-(7R,7'R,7''R,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5'-pentamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol	0
(-)-(7R,7'R,7''R,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5-tetramethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol	0
(-)-(7R,7'R,7''S,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5',5''-hexamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol	0
(-)-(7R,7'R,7''S,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5'-pentamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol	0
(-)-(7R,7'R,7''S,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5-tetramethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol	0
(-)-(7R,7'R,8S,8'S)-4'-hydroxy-3,3',4,5,5'-pentamethoxy-7,9':7',9-diepoxylignane	0
(-)-demethoxylpinoresinol	0
(-)-medioresinol	0
(1S,3R,7Z,9R,12S,13R,15R)-13-Hydroxy-3,7,12-trimethyl-13-prop-1-en-2-yl-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-diene-4,11-dione	0
(1S,7Z,9R,12S,13R,15R)-13-Hydroxy-3,7,12-trimethyl-13-propan-2-yl-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-diene-4,11-dione	0
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-\{4-[(2-methyl-1,3-thiazol-4-yl)methoxy]benzyl\}propyl]carbamate	0
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl glycolate	0
11,12-epoxy-5,6-seco-1,6(13)-tremuladien-5,12-olide	0
13-Hydroxymarasmene	0
14,15-dihydroajugapitin	0
14,15-dihydroclerodin	0
14-hydro-15-hydroxyajugachin A	0
14-hydro-15-hydroxyajugapitin	0
15-Hydroxymarasmen-3-one	0
15-epi-lupulin B	0
15-hydroxyajubractin C	0
1alpha,15-Dihydroxymarasmene	0
22-epi-methylatranone B	0
3-epi-14,15-dihydrocaryoptin	0
3-epi-caryoptin	0
3alpha,15-Dihydroxymarasmene	0
3beta-Dihydroxymarasmene	0
4-[(1S,3aR,4S,6aR)-4-(1,3-benzodioxol-5-yl)tetrahydrofuro[3,4-c]furan-1-yl]-2-methoxyphenol	0
4-epi-Ethiosolide	0
4alpha-hydroxypinoresinol	0
4beta-[(beta-D-glucopyranosyl)hydroxy]-pinoresinol	0
6-(7-methyloctyl)-1H,3H,4H,6H-furo[3,4-c]furan-1-one	0
6-hexyl-3-methyl-(3S,3aS,6R,6aR)-perhydrofuro[3,4-b]furan-2,4-dione	0
Agrocybolactone	0
Anhydromarasmone	0
Ascospiroketal A	0
Ascospiroketal B	0
Asperochrin E	0
Aspersclerotiorone C	0
Asteltoxin	0
Asteltoxin B	0
Asteltoxin C	0
Asteltoxin D	0
Asteltoxin E	0
Asteltoxin F	0
Atranone A	0
Atranone B	0
Atranone C	0
Atranone H	0
Atranone I	0
Atranone T	0
Atranone U	0
Avenaciolid 1	0
Avenaciolid 4	0
Avertoxin A	0
Avertoxin B	0
Avertoxin C	0
Avertoxin D	0
Cephalosporolide E	0
Cephalosporolide F	0
Cephalosporolide H	0
Cephalosporolide I	0
Clerodendrin A	0
Communiol D	0
Conosilane A	0
Dermatolactone	0
Diasteltoxin A	0
Diasteltoxin B	0
Diasteltoxin C	0
Dibetaeminin A	0
Dihydromarasmone	0
Discosiolide	0
Eremantholide A	0
Erythroskyrin	0
GS-8373	0
Gilluone A	0
Gymnodrimane D	0
Isoasteltoxin	0
Isomarasmone	0
Jodrellin A	0
LSM-4433	0
Mabetaarilactone A	0
Mabetaarilactone F	0
Mabetaarilactone acetonide	0
Manginoid E	0
Manginoid F	0
Marasmene	0
Marasmene B	0
Marasmone	0
NORCANTHARIDIN	48
Neglectine A	0
Nesteretal A	0
No. 2106 A	0
Penisporolide B	0
Protulactone A	0
Pseudonocardide D	0
Purpurogenolide A	0
Pyrenolide D	0
Rubetaulanorol-beta	0
Sculponeatin C	0
Spiroleptosphol T1	0
Spiroleptosphol T2	0
Spiroleptosphol W	0
Spiromabetaaritone	0
Syringolide 1	0
Syringolide 2	0
Taichunin A	0
Trichodermaketone A	0
Trichodermaketone B	0
Trichodermaketone E	0
V214w	0
Varioxiranol L	0
Velleratretraol	0
Virgineol	0
Xylobovide	0
[(1S,3R,7Z,9R,12S,13R,15R)-13-Butan-2-yl-13-hydroxy-3,12-dimethyl-4,11-dioxo-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-dien-7-yl]methyl acetate	0
ajubractin A	0
ajubractin B	0
ajubractin C	0
ajubractin D	0
ajubractin E	0
ajugapitin	0
alpha-mannofuranuronic acid gamma-lactone	0
aplysiallene	0
areptin A	0
areptin B	0
buddlenol C	0
caryoptin	0
clerodin	0
darunavir +	0
demethoxyaschantin	0
dihydrocanadensolide	0
ficusequilignan A	0
ivain II	0
lupulin A	0
pinoresinol +	7
salicifoliol	0
sesaminol	0
sesaminol 2-O-beta-D-gentiobioside	0
sesaminol 2-O-beta-D-glucoside	0
sporothriolide	0
stemocurtisine	0
stemocurtisine N-oxide	0
syringaresinol +	1

paths to the root